Previous close | 0.4300 |
Open | 0.4140 |
Bid | 0.4320 x N/A |
Ask | 0.4500 x N/A |
Day's range | 0.4140 - 0.4140 |
52-week range | 0.3400 - 1.3150 |
Volume | |
Avg. volume | 0 |
Market cap | N/A |
Beta (5Y monthly) | N/A |
PE ratio (TTM) | N/A |
EPS (TTM) | N/A |
Earnings date | 13 May 2024 - 19 May 2024 |
Forward dividend & yield | N/A (N/A) |
Ex-dividend date | N/A |
1y target est | N/A |
CHICAGO, April 22, 2024--Exicure, Inc. ("Exicure" or the "Company") (Nasdaq: XCUR), announced today it received a notice of non-compliance from Nasdaq Stock Market LLC ("Nasdaq") on April 17, 2024 notifying the Company that, as a result of the Company’s failure to timely file its Annual Report on Form 10-K for the year ended December 31, 2023 (the "Form 10-K"), the Company is not in compliance with Nasdaq Listing Rule 5250(c)(1) (the "Rule"), which requires listed companies to timely file all pe
CHICAGO, February 05, 2024--Exicure, Inc., (NASDAQ:XCUR) a company that historically developed nucleic acid therapies, and Bluejay Therapeutics, Inc., a private clinical stage biopharmaceutical company focused on viral and liver diseases, announced today that Bluejay Therapeutics, Inc. ("Bluejay") and Exicure, Inc. ("Exicure") entered into a patent license agreement to develop cavrotolimod for potential treatment for hepatitis.
Exicure, Inc. ( NASDAQ:XCUR ) shares have had a horrible month, losing 25% after a relatively good period beforehand...